Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ELTX vs. AMRN, TRVI, CRBP, CYBN, ACRV, MGNX, XBIT, ENTA, LXRX, and ADCTShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Amarin (AMRN), Trevi Therapeutics (TRVI), Corbus Pharmaceuticals (CRBP), Cybin (CYBN), Acrivon Therapeutics (ACRV), MacroGenics (MGNX), XBiotech (XBIT), Enanta Pharmaceuticals (ENTA), Lexicon Pharmaceuticals (LXRX), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Amarin Trevi Therapeutics Corbus Pharmaceuticals Cybin Acrivon Therapeutics MacroGenics XBiotech Enanta Pharmaceuticals Lexicon Pharmaceuticals ADC Therapeutics Amarin (NASDAQ:AMRN) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Which has stronger earnings & valuation, AMRN or ELTX? Elicio Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$306.91M0.70-$59.11M-$0.09-5.83Elicio Therapeutics$2.30M24.02-$35.19M-$6.95-0.74 Is AMRN or ELTX more profitable? Elicio Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Elicio Therapeutics N/A -555.45%-177.34% Does the media prefer AMRN or ELTX? In the previous week, Elicio Therapeutics had 1 more articles in the media than Amarin. MarketBeat recorded 2 mentions for Elicio Therapeutics and 1 mentions for Amarin. Elicio Therapeutics' average media sentiment score of 0.00 beat Amarin's score of -0.50 indicating that Elicio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Elicio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AMRN or ELTX? Amarin has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Does the MarketBeat Community favor AMRN or ELTX? Amarin received 838 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Elicio Therapeutics an outperform vote while only 74.36% of users gave Amarin an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84474.36% Underperform Votes29125.64% Elicio TherapeuticsOutperform Votes685.71% Underperform Votes114.29% Do institutionals & insiders believe in AMRN or ELTX? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend AMRN or ELTX? Elicio Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 95.31%. Given Elicio Therapeutics' higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Elicio Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryElicio Therapeutics beats Amarin on 10 of the 17 factors compared between the two stocks. Ad DTII've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.25M$6.58B$5.14B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-0.7410.93132.3717.61Price / Sales24.02363.851,231.9986.52Price / CashN/A52.5940.0636.27Price / Book-2.9110.176.956.36Net Income-$35.19M$153.36M$119.48M$226.00M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.77 of 5 stars$5.12+2.2%$10.00+95.3%-15.5%$55.25M$2.30M-0.74N/AAMRNAmarin0.1467 of 5 stars$0.52+6.1%N/A-37.4%$215.56M$306.91M-5.83360TRVITrevi Therapeutics3.4429 of 5 stars$2.73-1.4%$7.43+172.1%+113.1%$209.86MN/A-6.3020CRBPCorbus Pharmaceuticals4.8649 of 5 stars$16.82+4.6%$65.86+291.5%+249.6%$204.91M$880,000.00-3.4840CYBNCybin1.4707 of 5 stars$10.13-9.2%$138.00+1,262.3%N/A$202.50MN/A-1.5550Analyst ForecastAnalyst RevisionHigh Trading VolumeACRVAcrivon Therapeutics2.745 of 5 stars$6.44-0.9%$23.67+267.5%+62.9%$200.54MN/A-2.3958Analyst RevisionMGNXMacroGenics3.8654 of 5 stars$3.19-2.7%$7.63+138.7%-57.0%$200.44M$58.75M-2.02430XBITXBiotech0.8956 of 5 stars$6.56+1.1%N/A+77.8%$199.95M$4.01M-6.01100Positive NewsENTAEnanta Pharmaceuticals2.9646 of 5 stars$9.35+3.0%$20.00+113.9%+1.6%$192.40M$71.96M-1.72145LXRXLexicon Pharmaceuticals1.993 of 5 stars$0.78-3.7%$6.00+669.1%-31.6%$192.09M$1.20M-1.04285Analyst RevisionADCTADC Therapeutics2.8942 of 5 stars$1.94-2.0%$8.25+325.3%+177.9%$187.58M$69.56M-0.81310Positive News Related Companies and Tools Related Companies AMRN Competitors TRVI Competitors CRBP Competitors CYBN Competitors ACRV Competitors MGNX Competitors XBIT Competitors ENTA Competitors LXRX Competitors ADCT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts